Elizabeth I. Buchbinder, MD, discusses findings from a retrospective study evaluating the resumption of nivolumab maintenance therapy in patients with advanced melanoma who discontinued treatment with the combination of nivolumab and ipilimumab due to immune-related adverse effects.

Related Keywords

Boston , Massachusetts , United States , Dana Farber Cancer Institute , Elizabethi Buchbinder , , Harvard Medical School , D , Melanoma , Asco Annual Meeting , Nivolumab , Immune Related Adverse Effects ,